Meeting
2023 ASCO Genitourinary Cancers Symposium
A multi-center, open-label, randomized dose expansion study of PF-06821497, a potent and selective inhibitor of enhancer of zeste homolog 2 (EZH2), in patients with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Mariona Calvo
Medical Oncology Department, Catalan Institute of Oncology, Hospitalet, Barcelona, Spain
Mariona Calvo , Konstantin Penkov , Alexander I. Spira , Irene Moreno Candilejo , Neal D. Shore , Tian Zhang , Begoña Mellado-Gonzalez , Teresa Alonso Gordoa , Luis Paz-Ares Rodriguez , Stefano R. Tarantolo , Juan José Soto , Robert S. Alter , Claudia Andreu-Vieyra , Timothy Bowler , Arnab K Maity , Subramanian Hariharan , Michael Thomas Schweizer
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03460977
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS282)
DOI
10.1200/JCO.2023.41.6_suppl.TPS282
Abstract #
TPS282
Poster Bd #
Q4
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
A phase Ib/II open-label study of tazemetostat (TAZ) plus enzalutamide (E) or abiraterone/prednisone (A/P) in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Wassim Abida
Poster
2021 Genitourinary Cancers Symposium
A phase III, randomized, open-label, study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy (NHT) in patients (pts) with metastatic, castration-resistant prostate cancer (mCRPC).
First Author: Neeraj Agarwal
Poster
2019 Genitourinary Cancers Symposium
ProSTAR: A phase Ib/II study of CPI-1205, a small molecule inhibitor of EZH2, combined with enzalutamide (E) or abiraterone/prednisone (A/P) in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Mary-Ellen Taplin
Poster
2024 ASCO Genitourinary Cancers Symposium
A phase I, open-label, dose-finding study of fatty acid synthase (FASN) inhibitor TVB-2640 administered in combination with enzalutamide (Enza) in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Pier VItale Nuzzo